Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.
Based on fair quality Level 3 evidence, Lu et al.(1) note that glatiramer acetate (GA) exposure was not associated with lower mean birthweight, lower mean gestational age, preterm birth (37 weeks), congenital anomaly, or spontaneous abortion. However, GA was given an indeterminate recommendation because further research is needed. The results are not compelling: 3 of the 4 existing human studies of GA were small case series.(1.)